Early Clinical Study of Allogenic CAR-NK Targeted CD19 (JD010) in the Treatment of Adult Relapsed or Refractory B-cell Malignancies
Latest Information Update: 16 Dec 2022
At a glance
- Drugs JD 010 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2022 New trial record